$7.53 -0.36 (%) Immunogen Inc - NASDAQ

Mar. 3, 2015 | 11:55 AM

Partner Headlines

  1. Here's Why Oppenheimer Upgraded ImmunoGen To Outperform

    Benzinga | Feb. 6, 2015 | 10:45AM EST
  2. Benzinga's Top #PreMarket Losers

    Benzinga | Feb. 2, 2015 | 08:23AM EST
  3. Gulf Resources (GURE) Soars on Natural Gas Discovery, ImmunoGen (IMGN) and Synaptics (SYNA) ...

    GuruFocus | Jan. 31, 2015 | 20:55PM EST
  4. ImmunoGen Shares Surge 30% Following Earnings

    Benzinga | Jan. 30, 2015 | 14:16PM EST
  5. Earnings Scheduled For January 30, 2015

    Benzinga | Jan. 30, 2015 | 04:57AM EST
  6. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

    Benzinga | Jan. 12, 2015 | 11:03AM EST
  7. Roche Halts Alzheimer's Trial

    IBD | Dec. 19, 2014 | 18:47PM EST
  8. Mid-Day Losers From December 19: ImmunoGen, NQ Mobile And More

    Benzinga | Dec. 19, 2014 | 13:33PM EST
  9. Juno Therapeutics IPO Caps Big Year In Biotech Deals

    IBD | Dec. 19, 2014 | 12:47PM EST
  10. Top 3 Short Ideas Among Friday's Losers

    Benzinga | Dec. 19, 2014 | 12:21PM EST
  11. Roche Drugs For Alzheimer's, Breast Cancer Disappoint

    IBD | Dec. 19, 2014 | 11:31AM EST
  12. Benzinga's Top #PreMarket Losers

    Benzinga | Dec. 19, 2014 | 09:33AM EST
  13. #PreMarket Movers From December 19, 2014: NQ Mobile, BlackBerry, CarMax And More

    Benzinga | Dec. 19, 2014 | 09:20AM EST
  14. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus | Jul. 30, 2014 | 19:21PM EST
  15. Wednesday's Biggest Movers

    Benzinga | Jun. 25, 2014 | 16:49PM EST
  16. Shares Of ImmunoGen Down On Morgan Stanley's Bearish Initiation

    Benzinga | Jun. 25, 2014 | 08:26AM EST
  17. Benzinga's Top Initiations

    Benzinga | Jun. 25, 2014 | 08:21AM EST
  18. UPDATE: Canaccord Genuity Initiates Coverage on ImmunoGen Ahead of Phase 3 Data

    Benzinga | Apr. 16, 2014 | 09:29AM EST
  19. ImmunoGen Says Initial Research Shows New Dosing Approach for IMGN853 Achieves Objective

    Benzinga | Apr. 8, 2014 | 16:17PM EST
  20. IDEXX Laboratories Elects Daniel Junius to Board of Directors

    Benzinga | Mar. 11, 2014 | 16:24PM EST
  21. US Stock Futures Down Ahead Of Wal-Mart Earnings, Economic Data

    Benzinga | Feb. 20, 2014 | 07:05AM EST
  22. CytomX Therapeutics, ImmunoGen Announce Strategic Collaboration

    Benzinga | Jan. 9, 2014 | 06:39AM EST
  23. ImmunoGen Announces Activity Reported with SAR3419 Plus Rituxan In Difficult-to-Treat Patient Population at ASH

    Benzinga | Dec. 9, 2013 | 11:31AM EST
  24. US Stock Futures Edge Lower Ahead Of FOMC Minutes, Economic Data

    Benzinga | Nov. 20, 2013 | 07:00AM EST
  25. ImmunoGen Announces Approval of Roche's Kadcyla in EU

    Benzinga | Nov. 20, 2013 | 05:56AM EST
  26. UPDATE: Morgan Stanley Downgrades ImmunoGen Following Phase 2 Failure of IMGN901

    Benzinga | Nov. 11, 2013 | 10:00AM EST
  27. Benzinga's Top #PreMarket Losers

    Benzinga | Nov. 11, 2013 | 08:19AM EST
  28. ImmunoGen Announces License Agreement with Novartis

    Benzinga | Nov. 11, 2013 | 06:38AM EST
  29. Mid-Afternoon Market Update: Marvell Rises on KKR Stake While Orbitz Gives Up Last Week's Gains

    Benzinga | Nov. 5, 2013 | 15:23PM EST
  30. Mid-Day Market Update: BroadSoft Drops On Q3 Results; Endo Health Shares Spike Higher

    Benzinga | Nov. 5, 2013 | 12:29PM EST
  31. Mid-Morning Market Update: Markets Open Lower; CVS Caremark Lifts Outlook

    Benzinga | Nov. 5, 2013 | 10:36AM EST
  32. Benzinga's Top #PreMarket Losers

    Benzinga | Nov. 5, 2013 | 08:16AM EST
  33. US Stock Futures Signal Lower Start On Wall Street

    Benzinga | Nov. 5, 2013 | 07:11AM EST
  34. ImmunoGen Presents SAR566658 Clinical Findings at AACR-NCI-EORTC Conference

    Benzinga | Oct. 20, 2013 | 17:00PM EST
  35. US Stock Futures Up; J.P. Morgan Earnings In Focus

    Benzinga | Oct. 11, 2013 | 07:13AM EST
  36. ImmunoGen Announces New License Agreement with Novartis

    Benzinga | Oct. 11, 2013 | 06:54AM EST
  37. ImmunoGen Announces Positive Results from Kadcyla Phase III Trial, TH3RESA at ECC 2013

    Benzinga | Sep. 28, 2013 | 09:23AM EST
  38. The 'L' In CANSLIM Stands For Leaders, Not Laggards

    IBD | Sep. 11, 2013 | 18:29PM EST
  39. UPDATE: Oppenheimer Downgrades ImmunoGen to Perform on Valuation

    Benzinga | Jan. 28, 2013 | 02:30AM EST
  40. Earnings Scheduled For January 25, 2013

    Benzinga | Jan. 24, 2013 | 19:53PM EST
  41. From Earlier: Amgen Takes Third License for Rights to Use ImmunoGen's TAP Technology

    Benzinga | Dec. 19, 2012 | 02:10AM EST
  42. ImmunoGen Clinical Results of IMGN901

    Benzinga | Dec. 10, 2012 | 09:52AM EST
  43. A Peek Into the Market Before the Trading Begins

    Benzinga | Nov. 26, 2012 | 01:40AM EST
  44. ImmunoGen Announces Dr. Charles Morris as New Chief Development Officer

    Benzinga | Nov. 25, 2012 | 23:33PM EST
  45. ImmunoGen Inc. Reports Operating Results (10-Q)

    GuruFocus | Oct. 31, 2012 | 07:02AM EST
  46. It's All Bad News For ImmunoGen After 1Q13 Earnings Release

    Benzinga | Oct. 26, 2012 | 10:07AM EST
  47. Health Care Sector Wrap

    FoxBusiness | Aug. 27, 2012 | 10:44AM EST
  48. Benzinga's Top Pre-Market Gainers

    Benzinga | Aug. 27, 2012 | 02:13AM EST
  49. A Peek Into The Market Before The Trading Starts

    Benzinga | Aug. 27, 2012 | 01:22AM EST
  50. ImmunoGen

    IBD | Aug. 22, 2012 | 12:46PM EST
Trading Center